Speakers - Sachs Associates

More documents

Recommendations

Info

CONTACT Vincent Lefaiconnier Chief Commercial Officer ADDRESS Vexim 75 rue Saint Jean 31130 Balma France TELEPHONE +33 4 61 48 48 38 FAX +33 5 61 48 95 19 EMAIL v.lefauconnier@vexim.fr YEAR FOUNDED 2006 Vexim www.vexim.fr FINANCIAL SUMMARY Half-year 2012 sales: €1.1m (+93% over 12 months) Full-year 2011 sales: €1.2m 2011 net income: -€5.1m COMPANY PROFILE Based in Balma, near Toulouse (France), Vexim is a medical device specialist created in February 2006. The company has specialised in the creation and marketing of mini-invasive solutions for treating spinal pathologies. Benefitting from the financial support of its longstanding shareholders, Truffle Capital and Banexi Venture, and from OSEO public subsidies, Vexim has designed and developed the SpineJack®, a unique implant capable of repairing a deformed or fractured vertebra and correcting the anatomy of the spinal column. The Company currently has 35 staff. It has its own sales teams in France, Germany and Italy, as well as distributors in Spain, Portugal, Italy, Turkey, Argentina and South Africa. The company’s 2011 sales amounted to €1.2m and its 2011 gross margin was 58.3%. Vexim was successfully listed on NYSE Alternext in May 2012, raising €11m. The company’s 1st half 2012 sales achieved €1.1m, almost equaling the whole 2011 financial year performance. MANAGEMENT Vincent Gardès, Chief Executive Officer Vincent Lefauconnier, Chief Commercial Officer t back :: next u WELCOME PHARMA LICENSING GROUPS SPEAKERS PRESENTING COMPANIES SUPPORTING ORGANISATIONS ORGANISERS
CONTACT Jakob Knudsen Chief Executive Officer ADDRESS Blokken 45 3460 Birkerød Denmark TELEPHONE +45 22 261 355 EMAIL jk@virogates.com YEAR FOUNDED 2001 Virogates www.virogates.com COMPANY PROFILE ViroGates A/S is committed to improve the screening and monitoring of patients in a hospital setting and healthy individuals in risk of developing life style related diseases. ViroGates has developed an ELISA (enzyme-linked immunosorbent assay) based suPAR (soluble urokinase Plasminogen Activator Receptor) test that, in clinical settings, has shown to predict mortality and disease progression. More than 120.000 patients have to date been tested with suPARnostic® and studies have been reported in more than 80 peer reviewed articles. ViroGates has recently (2012) launched its suPARnostic Quick Triage test based on lateral flow technology. The Quick Triage products provide results in 20 minutes. ViroGates product portfolio consists of three fully developed products with CE-IVD approvals. The ELISA Standard kit marketed for clinical research and the ELISA Flex kit marketed for routine use at central laboratories in addition to the ELISA products, ViroGates has recently (2012) launched its suPARnostic Quick Triage test based on lateral flow technology. The Quick Triage product provide results in 20 minutes. Sales and marketing is carried out through ViroGates’ network of distributors. ViroGates has more than 20 distribution partners worldwide MANAGEMENT Jakob Knudsen, Chief Executive Officer t back :: next u WELCOME PHARMA LICENSING GROUPS SPEAKERS PRESENTING COMPANIES SUPPORTING ORGANISATIONS ORGANISERS
Page 1 and 2:
B I O T E C H I N E U R O P E I N V
Page 3 and 4:
Events Diary For regular updates, s
Page 5 and 6:
Speakers Alexey Eliseev, Managing D
Page 7 and 8:
Speakers Blake M. Paterson, Co-Foun
Page 9 and 10:
Speakers David Slack, Head of Corpo
Page 11 and 12:
Speakers Frank Grams, VP, Head Alli
Page 13 and 14:
Speakers Iain Buchanan, CEO, NOXXON
Page 15 and 16:
Speakers Juhani Lahdenperä, CEO, H
Page 17 and 18:
Speakers Marcel Zwaal, CBO, DCPrime
Page 19 and 20:
Speakers Paul Higham, Managing Dire
Page 21 and 22:
Speakers Richard Goodfellow, CEO, S
Page 23 and 24:
Speakers Søren Moller, Managing In
Page 25 and 26:
CONTACT Robert F Burns, PhD Chief E
Page 27 and 28:
CONTACTS Rostislav Raykov Chief Exe
Page 29 and 30:
CONTACTS Vincent Charlon PhD, CEO Z
Page 31 and 32:
CONTACTS Dr Bassam Damaj Chairman,
Page 33 and 34:
CONTACT Carina Schmidt Chief Execut
Page 35 and 36:
CONTACT Mr Richard Godfrey Chief Ex
Page 37 and 38:
CONTACTS Tom Kronbach, PhD Chief Ex
Page 39 and 40:
CONTACTS Andreas Caduff, PhD Chief
Page 41 and 42:
CONTACTS Dr Blake Paterson Co-Found
Page 43 and 44:
CONTACT Wolfgang Kintzel Chief Exec
Page 45 and 46:
CONTACT Mike Romanos PhD Chief Exec
Page 47 and 48:
CONTACT Harry Welten, MBA Chief Fin
Page 49 and 50: CONTACT Barbara Stiefel Office Mana
Page 51 and 52: CONTACTS Ana Martinez Assistant Jua
Page 53 and 54: CONTACTS Dr Rudi D Neirinckx Chief
Page 55 and 56: CONTACT Martin Bonde, PhD, BComm Ch
Page 57 and 58: CONTACT Benedikt Timmerman Chief Ex
Page 59 and 60: CONTACT Malcolm Weir Chief Executiv
Page 61 and 62: CONTACTS Mr Paul Higham Chief Execu
Page 63 and 64: CONTACTS Kevin FitzGerald Chief Ope
Page 65 and 66: CONTACT Roel Q. J Schaapveld, PhD,
Page 67 and 68: CONTACT Maaike Vogelezang Managemen
Page 69 and 70: CONTACT Tom Johnston Chief Executiv
Page 71 and 72: CONTACTS Aaron Powers President Dav
Page 73 and 74: CONTACTS General and Media Contact
Page 75 and 76: CONTACTS Martin Welschof Chief Exec
Page 77 and 78: CONTACTS Carlos Buesa Chief Executi
Page 79 and 80: CONTACTS Nick McCooke Chief Executi
Page 81 and 82: CONTACT Dr Erik Buntinx Chief Execu
Page 83 and 84: CONTACT Michael Altorfer, Ph.D. Hea
Page 85 and 86: CONTACT Matthew B. Lehman Chief Ope
Page 87 and 88: ADDRESS Otto-Hahn-Strasse 15 D- 442
Page 89 and 90: CONTACT Dr Roman Schenk Chief Execu
Page 91 and 92: CONTACTS Dr Hans Fliri Chairman Sim
Page 93 and 94: CONTACTS Dr Raúl Insa Chief Execut
Page 95 and 96: CONTACT Dr Johanna Holldack, MD Chi
Page 97 and 98: CONTACT Eduardo Bravo (speaker) Man
Page 99: CONTACTS Piers Morgan Chief Financi
Page 103 and 104: CONTACTS Dr Sonja Reingruber Chief
Page 105 and 106: Supporting Organisations Citigate D
Page 107 and 108: Supporting Organisations Life Scien
Page 109 and 110: Supporting Organisations Swiss Biot
Page 111 and 112: Supporting Organisations Torreya Pa
Page 113: B I O T E C H I N E U R O P E I N V
show all

Speakers - Sachs Associates

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?